Market Watch: Bajaj Finance Launches QIP, Tata Power Announces Leadership Transition, and Alivus Life Acquires Majority Stake in IQGen-X Pharma

Indian markets saw a flurry of corporate updates this week, ranging from capital raises and leadership changes to regulatory actions and ESG milestones across major listed entities.

Bajaj Finance, the country's largest private sector non-banking financial company (NBFC), launched a qualified institutional placement (QIP) on Wednesday. The firm aims to raise up to ₹11,700 crore ($1.25 billion), setting an indicative issue price of ₹1,025 per share. This represents a 5 per cent discount to its last closing price on the National Stock Exchange (NSE) and sits above the Securities and Exchange Board of India’s (SEBI) floor price of ₹992.25 per share.

In the power sector, Tata Power announced a leadership transition plan on Wednesday. The board approved the elevation of Sanjay Banga, currently president of its renewables business, as Chief Executive Officer-designate. He is set to take over as managing director and CEO for a five-year term beginning May 1, 2027, subject to shareholder approval.

Kutch Copper Ltd (KCL), a unit of Adani Enterprises Ltd operating one of the world’s largest single-location copper smelters, secured the Veramark Assurance certification. Formerly known as Copper Mark, the independent assurance framework evaluates environmental, social, and governance (ESG) performance. KCL is now the first Indian producer to be recognized under this global framework for responsible copper production.

In mining updates, The Sandur Manganese and Iron Ores Ltd received environmental clearance from the Ministry of Environment, Forest and Climate Change (MoEF&CC). The approval permits the company to increase the production capacity of its iron ore mine from 7.85 million tonnes per annum (MTPA) to 9.42 MTPA. Concurrently, the clearance allows a reduction in its manganese ore production capacity from 1.34 MTPA to 0.733 MTPA at its mining lease (No. 2678), which covers 1,860.10 hectares.

In merger and acquisition activity, Alivus Life Sciences (formerly Glenmark Life Sciences) is acquiring a 76 per cent majority stake in IQGen-X Pharma Private Limited. The transaction involves an all-cash consideration of ₹9.12 crore (₹91.2 million). On November 11, 2026, Alivus executed a formal Shareholders’ Agreement (SHA) with IQGen-X Pharma and its continuing founders to finalise governance terms ahead of the deal’s targeted closing around December 6.

Finally, regulatory updates emerged in the pharmaceutical sector as Aurobindo Pharma Ltd informed stock exchanges regarding an inspection of its step-down wholly-owned subsidiary, Lannett Company LLC. The US Food and Drug Administration (US FDA) classified the inspection at the Seymour facility in Indiana, US, as “official action indicated” (OAI). The inspection took place between August 17 and 21, 2026, resulting in four observations. Aurobindo Pharma stated it responded to all four observations within the stipulated timeframe.

"The recent wave of corporate developments highlights how established Indian enterprises are actively strengthening their balance sheets, optimizing operational capacities, and executing strategic acquisitions. From Bajaj Finance utilizing the QIP route for capital mobilization to Alivus Life Sciences consolidating its market presence through tactical M&A, these moves reflect a dynamic corporate landscape. At the same time, regulatory clearances and ESG recognitions underline the increasing importance of compliance and sustainable governance in large-scale operations." — Dr. Shishir Gupta, Founder & CEO, StartupLanes